Diagnosing feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection: an update for clinicians.

摘要: With the commercial release in Australia 2004 of a vaccine against feline immunodeficiency virus (FIV; Fel-O-Vax FIV®), landscape for FIV diagnostics shifted substantially. Point-of-care (PoC) antibody detection kits, which had been mainstay diagnosing infection since early 1990s, were no longer considered accurate to use FIV-vaccinated cats, because production vaccine-induced antibodies that indistinguishable from those produced natural infections. Consequently, attention alternative diagnostic methods such as nucleic acid detection. However, over past 5 years we have published series studies emphasising PoC test kits vary their methodology, resulting differing accuracy cats. Importantly, demonstrated two commercially available (Witness™ and Anigen Rapid™) able accurately distinguish between FIV-infected concluding testing with either kit offers an PCR testing. This review summarises pertinent findings our work variety peer-reviewed research journals inform veterinarians (particularly Australia, New Zealand Japan, where is currently available) about how approach diagnosis has shifted. Included this investigating performance three cats recommendations infection; effect primary vaccination (three vaccines, 4 weeks apart) on performance; regarding annual detect 'vaccine breakthroughs'; potential off-label saliva using some kits. We also investigated same brands leukaemia (FeLV) diagnosis, both blood specimens. Based these results, discuss confirmatory when are presented positive FeLV result. Finally, conclude results largest most recent seroprevalence study conducted date.